Published online 28 April 2008
Haematologica, Vol 93, Issue 6, 921-924 doi:10.3324/haematol.12165
Copyright © 2008 by Ferrata Storti Foundation
Daniela Cilloni1 ,
Francesca Messa1 ,
Francesca Arruga1 ,
Ilaria Defilippi1 ,
Enrico Gottardi1 ,
Milena Fava1 ,
Sonia Carturan1 ,
Renata Catalano1 ,
Enrico Bracco1 ,
Emanuela Messa1 ,
Paolo Nicoli1 ,
Daniela Diverio2 ,
Miguel A. Sanz3 ,
Giovanni Martinelli4 ,
Francesco Lo-Coco5 ,
Giuseppe Saglio1
Haematologica, Vol 93, Issue 6, 921-924 doi:10.3324/haematol.12165
Copyright © 2008 by Ferrata Storti Foundation
Brief Report |
Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy
1 Dept. of Clinical and Biological Sciences, University of Turin, Italy;
2 Dept. of Cellular Biotechnologies and Hematology, University La Sapienza, Rome, Italy;
3 Dept of Medical Biopathology, Hospital Universitario La Fe, Valencia, Spain;
4 Dept. of Hematology, Seragnoli Institute, University of Bologna, Bologna, Italy and
5 Department of Biopathology, University Tor Vergata, Rome, Italy
Correspondence: Daniela Cilloni, M.D, PhD, Dept. of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Gonzole 10, 10043 Orbassano, Turin, Italy. E-mail:daniela.cilloni{at}unito.it
ABSTRACT
The Wilms’ tumor gene WT1 is a reliable marker for minimal residual disease assessment in acute leukemia patients. The study was designed to demonstrate the potential use of WT1 to establish quality of remission in acute leukemia patients for early identification of patients at high risk of relapse. A prospective study based on a quantitative Real–Time PCR (TaqMan) assay in 562 peripheral blood samples collected from 82 acute leukemia patients at diagnosis and during follow-up was established. The evaluation of WT1 in peripheral blood samples after induction chemotherapy can distinguish the continuous complete remission patients from those who obtain only an "apparent" complete remission and who could relapse within a few months. WT1 helps identify patients at high risk of relapse soon after induction chemotherapy allowing post-induction therapy in high risk patients to be intensified.
Key words: WT1, minimal residual disease, acute leukemia, RQ-PCR.
This article has been cited by other articles:
 |
|
 |
|
  D. Cilloni, A. Renneville, F. Hermitte, R. K. Hills, S. Daly, J. V. Jovanovic, E. Gottardi, M. Fava, S. Schnittger, T. Weiss, et al. Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study J. Clin. Oncol., November 1, 2009; 27(31): 5195 - 5201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Borrello, H. I. Levitsky, W. Stock, D. Sher, L. Qin, D. J. DeAngelo, E. P. Alyea, R. M. Stone, L. E. Damon, C. A. Linker, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML) Blood, August 27, 2009; 114(9): 1736 - 1745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Bene and J. S. Kaeda How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet Haematologica, August 1, 2009; 94(8): 1135 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. N. Berneman, A. Van de Velde, A. Van Driessche, N. Cools, B. Stein, G. Nijs, K. Vermeulen, K. Pieters, W. A. Schroyens, A. P. Gadisseur, et al. Immunogenicity and Antileukemic Activity of Dendritic Cells Electroporated with Wilms' Tumor WT1 mRNA: A Phase I/II Trial in Acute Myeloid Leukemia Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 830 - 830. [Abstract]
|
|